Search - tctmd.com

Displaying 1 - 20 of 724

Sort: Relevancy | Date

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

News Conference News ACC 2026

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Michael O'Riordan

March 29, 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

News Conference News ACC 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Yael L. Maxwell

March 28, 2026

No Major Progress on Making CV Care More Affordable: JACC Stats

News Daily News

No Major Progress on Making CV Care More Affordable: JACC Stats

March 18, 2026

Oral Anticoagulation Alone Best for Stable CAD Patients With AF: Meta-analysis

News Daily News

Oral Anticoagulation Alone Best for Stable CAD Patients With AF: Meta-analysis

Yael L. Maxwell

March 12, 2026

Large Variability in Use of Invasive Strategy for Type 1 NSTEMI: NCDR

News Conference News CRT 2026

Large Variability in Use of Invasive Strategy for Type 1 NSTEMI: NCDR

Michael O'Riordan

March 11, 2026

DOBERMANN: Dobutamine and Tocilizumab Show Promise in Pre-Shock Patients

News Conference News CRT 2026

DOBERMANN: Dobutamine and Tocilizumab Show Promise in Pre-Shock Patients

March 09, 2026

CRT 2026: What to Expect in Washington, DC

News Conference News CRT 2026

CRT 2026: What to Expect in Washington, DC

March 04, 2026

Healthy Lifestyle Plus GLP-1s Yields Bigger CV Reduction Than Drugs Alone

News Daily News

Healthy Lifestyle Plus GLP-1s Yields Bigger CV Reduction Than Drugs Alone

Michael O'Riordan

March 03, 2026

Statins Work for Primary Prevention Even in Low-risk Patients With Type 2 Diabetes

News Daily News

Statins Work for Primary Prevention Even in Low-risk Patients With Type 2 Diabetes

January 05, 2026

Year in Review: DCBs Big in Coronary News, Along With Beta-blockers in STEMI

News Daily News

Year in Review: DCBs Big in Coronary News, Along With Beta-blockers in STEMI

Yael L. Maxwell

December 29, 2025

Year in Review: Top Prevention Stories of 2025

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

News Conference News AHA 2025

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

November 13, 2025

Beta-blockers Not Helpful After MI in Patients With Preserved EF

News Conference News AHA 2025

Beta-blockers Not Helpful After MI in Patients With Preserved EF

Yael L. Maxwell

November 12, 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

News Conference News AHA 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

November 09, 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

News Conference News AHA 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

November 08, 2025

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure ANDES

News Conference News TCT 2025

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure: ANDES

Yael L. Maxwell

November 04, 2025

Evolocumab Wins for Primary Prevention in VESALIUS-CV

News Daily News

Evolocumab Wins for Primary Prevention in VESALIUS-CV

October 03, 2025

CVD Still the Leading Cause of Death and Disease Globally

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

CELEBRATE: Prehospital Platelet Inhibitor Zalunfiban Hits Mark in STEMI

News Daily News

CELEBRATE: Prehospital Platelet Inhibitor Zalunfiban Hits Mark in STEMI

Michael O'Riordan

September 23, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.